The University of Chicago Header Logo

Connection

Richard A. Larson to Neoplasms, Second Primary

Back to Details
This is a "connection" page, showing publications Richard A. Larson has written about Neoplasms, Second Primary.
Richard A. Larson
Connection Strength
4.248
Neoplasms, Second Primary
  1. Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy. Blood Adv. 2021 10 26; 5(20):4140-4148.
    View in: PubMed
    Score: 0.679
  2. The evolving challenge of therapy-related myeloid neoplasms. Best Pract Res Clin Haematol. 2013 Dec; 26(4):309-17.
    View in: PubMed
    Score: 0.388
  3. Cytogenetics, not just previous therapy, determines the course of therapy-related myeloid neoplasms. J Clin Oncol. 2012 Jul 01; 30(19):2300-2.
    View in: PubMed
    Score: 0.353
  4. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma. 2010 Jun; 51(6):995-1006.
    View in: PubMed
    Score: 0.308
  5. Therapy-related myeloid neoplasms. Haematologica. 2009 Apr; 94(4):454-9.
    View in: PubMed
    Score: 0.284
  6. Therapy-related myeloid leukemia. Semin Oncol. 2008 Aug; 35(4):418-29.
    View in: PubMed
    Score: 0.271
  7. Therapy-related myeloid leukaemia: a model for leukemogenesis in humans. Chem Biol Interact. 2005 May 30; 153-154:187-95.
    View in: PubMed
    Score: 0.216
  8. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003 Jul 01; 102(1):43-52.
    View in: PubMed
    Score: 0.186
  9. Inherited cancer predisposing mutations in patients with therapy-related myeloid neoplasms. Br J Haematol. 2023 02; 200(4):489-493.
    View in: PubMed
    Score: 0.182
  10. Myeloid leukemia after cytotoxic therapy and other hematotoxins. J Toxicol Environ Health A. 2000 Nov; 61(5-6):381-6.
    View in: PubMed
    Score: 0.158
  11. Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Adv. 2019 12 23; 3(24):4228-4237.
    View in: PubMed
    Score: 0.149
  12. Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood. 1999 Jul 15; 94(2):803-7.
    View in: PubMed
    Score: 0.145
  13. Myeloid leukemia after hematotoxins. Environ Health Perspect. 1996 Dec; 104 Suppl 6:1303-7.
    View in: PubMed
    Score: 0.121
  14. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am. 1996 Apr; 10(2):293-320.
    View in: PubMed
    Score: 0.115
  15. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood. 2011 Sep 29; 118(13):3525-7.
    View in: PubMed
    Score: 0.083
  16. Therapy-related myeloid sarcoma with an NPM1 mutation. Leuk Lymphoma. 2010 Nov; 51(11):2130-1.
    View in: PubMed
    Score: 0.079
  17. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem Biol Interact. 2010 Mar 19; 184(1-2):50-7.
    View in: PubMed
    Score: 0.074
  18. Genome-wide association study to identify novel loci associated with therapy-related myeloid leukemia susceptibility. Blood. 2009 May 28; 113(22):5575-82.
    View in: PubMed
    Score: 0.071
  19. MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility. Blood. 2008 Aug 01; 112(3):741-9.
    View in: PubMed
    Score: 0.066
  20. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia? Best Pract Res Clin Haematol. 2007 Mar; 20(1):29-37.
    View in: PubMed
    Score: 0.061
  21. Myelodysplasia: when to treat and how. Best Pract Res Clin Haematol. 2006; 19(2):293-300.
    View in: PubMed
    Score: 0.057
  22. Adult ALL: where are we and where are we going? Clin Adv Hematol Oncol. 2004 Jun; 2(6):342-4.
    View in: PubMed
    Score: 0.051
  23. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes Cancer. 2004 Mar; 39(3):217-23.
    View in: PubMed
    Score: 0.050
  24. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol. 2002 Sep 15; 20(18):3878-84.
    View in: PubMed
    Score: 0.045
  25. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
    View in: PubMed
    Score: 0.022
  26. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009 Jun; 23(6):1054-61.
    View in: PubMed
    Score: 0.018
  27. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007 Mar 01; 25(7):793-8.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.